Rotolo and colleagues demonstrated that CAR iNKT cells against CD19 could exert better tumor control as compared to CAR T cells against CD19 through the synergistic interaction with CD1d and CD19 on lymphoma (173). The gene discussed is CD19; the disease is neoplasm.